In New Jersey, Johnson & Johnson Innovation LLC announced 15 new collaborations spanning scientific areas including 3D printing, the microbiome and immunotherapy. These collaborations, which are focused on developing novel healthcare solutions in areas of high unmet need such as depression, cancer and diabetes, bring the total number of strategic transactions to more than 300 since the establishment of Johnson & Johnson Innovation.
“We continue to pursue transformative healthcare solutions and form collaborations that explore the cutting edge of scientific research to achieve our primary goal of improving the quality of patients’ lives,” said Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson.
Example collaborations include: a prototype artificial meniscus using a novel 3D printing system; a method to directly modulate the skin microbiome with applications in dermatology and the cosmetic industry; and RNA-based therapies and vaccines that enhance and fine tune immune response against specific infectious diseases and cancer.